-+ 0.00%
-+ 0.00%
-+ 0.00%

BMO Capital Downgrades Sarepta Therapeutics to Market Perform, Lowers Price Target to $70

Benzinga·06/16/2025 17:37:58
Listen to the news
BMO Capital analyst Kostas Biliouris downgrades Sarepta Therapeutics (NASDAQ:SRPT) from Outperform to Market Perform and lowers the price target from $120 to $70.